Sales share of Novo Nordisk's drugs in Chinese diabetes market 2021, by segment

Published by
Wenyi Zhang,
Jun 26, 2022
In November 2021, the Danish pharmaceutical company Novo Nordisk controlled more than half of the insulin market in China, in terms of sales volume. Founded in 1923, the firm specializes in producing diabetes medications, which accounted for around 80 percent of its annual sales revenue in 2021.

Market share of Novo Nordisk's medication sales in the diabetes care market in China in November 2021, by category

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

February 2022

Region

China

Survey time period

November 2021

Special properties

excluding Hong Kong and Taiwan

Citation formats
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$149 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Diabetes in China "

The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Diabetes in China

Demographics

5

Medications

6

Blood glucose monitoring equipment

8

Outlook

4

Further related statistics

17

Further Content: You might find this interesting as well

Statistics

Topics

Diabetes in ChinaObesity in the United StatesDiabetesVaccine industry in ChinaAging population in China
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Learn more about how Statista can support your business.
Menu